These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 8664620)
1. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Pharoah PD; Hollingworth W BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620 [TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785 [TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering for prevention of coronary heart disease: what policy now? Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865 [TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787 [TBL] [Abstract][Full Text] [Related]
6. Strategies for reducing coronary risk factors in primary care: which is most cost effective? Field K; Thorogood M; Silagy C; Normand C; O'Neill C; Muir J BMJ; 1995 Apr; 310(6987):1109-12. PubMed ID: 7742678 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain. Rubió PP Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Jönsson B; Johannesson M; Kjekshus J; Olsson AG; Pedersen TR; Wedel H Eur Heart J; 1996 Jul; 17(7):1001-7. PubMed ID: 8809516 [TBL] [Abstract][Full Text] [Related]
10. [Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective]. Klever-Deichert G; Hinzpeter B; Wendland G; Lauterbach K Med Klin (Munich); 2000 Jun; 95(6):305-13. PubMed ID: 10935414 [TBL] [Abstract][Full Text] [Related]
11. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective? Perreault S; Hamilton VH; Lavoie F; Grover S Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235 [TBL] [Abstract][Full Text] [Related]
12. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275 [TBL] [Abstract][Full Text] [Related]
13. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Hay JW; Wittels EH; Gotto AM Am J Cardiol; 1991 Apr; 67(9):789-96. PubMed ID: 1901436 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence. Thorvik E; Aursnes I; Kristiansen IS; Waaler HT Wien Klin Wochenschr; 1996; 108(8):234-43. PubMed ID: 8686314 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Tosteson AN; Weinstein MC; Hunink MG; Mittleman MA; Williams LW; Goldman PA; Goldman L Circulation; 1997 Jan; 95(1):24-30. PubMed ID: 8994412 [TBL] [Abstract][Full Text] [Related]
16. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO]. Simoons ML; Casparie AF Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain. Plans-Rubió P Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328 [TBL] [Abstract][Full Text] [Related]
19. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]